

ROSEAID Inc Introduces Telepathology Platform Version 2.0, Enhancing Remote Analytic and Collaboration Capabilities

The ROSEAID cloud-based AI centric platform empowers pathologists with advanced telepathology capabilities

HOUSTON, TEXAS, UNITED STATES, April 5, 2024 /EINPresswire.com/ -- ROSEAID Inc Unveils

Telepathology Platform Version 2.0, Elevating Remote Analytic and Collaboration Capabilities

“

We are thrilled to unveil Telepathology Platform Version 2.0, a testament to our ongoing commitment to innovation and excellence in telemedicine,”

CEO Joseph Rossi

ROSEAID Inc, a pioneer in telemedicine solutions, proudly introduces Telepathology Platform Version 2.0, the latest evolution in its remote analytic and collaborative technology. Building upon the success of prior releases, Version 2.0 represents a consistent leap forward in empowering healthcare professionals with advanced telepathology and deterministic capabilities.

With Version 2.0, ROSEAID Inc continues its commitment to innovation and excellence in telemedicine. This latest release further enhances remote detection capabilities, empowering pathologists to deliver superior patient care with increased efficiency and precision.

Key features of Version 2.0 include:

1. Advanced Image Analysis: Leveraging advanced image analysis algorithms pathologists can perform detailed analysis and interpretation of digital pathology images with unparalleled ease, accuracy and speed.
2. Enhanced Collaboration: new collaboration features, including real-time annotation and markup tools facilitate seamless communication and collaboration amongst pathologists, and other physicians regardless of their geographic location.
3. Streamlined Consultation Management: enables administrators and pathologists to track and manage consults simply.
4. Expanded Export Capabilities: seamless incorporation of notes and images into PDF reports,

streamlining the export process to case/laboratory management systems and ensuring compliance with regulatory standards.

"We are thrilled to unveil Telepathology Platform Version 2.0, a testament to our ongoing commitment to innovation and excellence in telemedicine," said Joseph Rossi, CEO at ROSEAID Inc. "With its advanced features and enhanced collaboration tools, Version 2.0 empowers pathologists to deliver superior patient care, regardless of their location, 24 x 7 in real time. We look forward to setting new standards for telepathology technology."

About ROSEAID Inc: ROSEAID Inc is a leading provider of telemedicine solutions, specializing in digital pathology and remote analytics. With a commitment to innovation and excellence, ROSEAID is dedicated to empowering healthcare professionals with advanced technologies to improve patient care and outcomes.

For more information about the platform or to schedule a demo, visit <https://roseaid.com/>. Follow us on LinkedIn.

Media contacts:

Email: media@roseaid.com

Harvey Rand

ROSEAID Inc

media@roseaid.com

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/701474411>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.